ARTICLE | Product Development
From Micro to Macro
May 4, 2009 7:00 AM UTC
Since its founding in 2000, Rosetta Genomics Ltd. has been building an IP estate and developing a portfolio of tests that measure expression of microRNA to diagnose disease. Now that Rosetta has launched its first three tissue-based tests for differential diagnosis of cancers and secured a partner to market them in the U.S., the company is getting to work on next-generation blood tests for de novo diagnosis of cancer.
"The reason why we chose to work on microRNA is that based on the biology, microRNAs are very sensitive, and you can detect them in body fluids," President and CEO Amir Avniel told BioCentury. "There is a very tight correlation between microRNA in serum and physiological changes."...